Evidence map›Paper›PMID 31193243›Full record

ArticleAmerican journal of ophthalmology case reports2019

Is subretinal surgery feasible for a non-responsive juxtafoveal type 2 choroidal neovascular membrane?

Hugo Quiroz-Mercado, Andrés Lisker-Cervantes, Luis Arroyo, Naresh Mandava, Frank S Siringo, Miguel Paciuc-Beja, Roberto Gonzalez-Salinas

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of ophthalmology case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Hugo Quiroz-MercadoResearch Department, Asociación para Evitar la Ceguera, IAP, Mexico City, PO 04030, Mexico.
Andrés Lisker-CervantesRetina Department, Asociación para Evitar la Ceguera, IAP, Mexico City, PO 04030, Mexico.
Luis ArroyoRetina Department, Asociación para Evitar la Ceguera, IAP, Mexico City, PO 04030, Mexico.
Naresh MandavaUniversity of Colorado, Denver, CO. United States.
Frank S SiringoUniversity of Colorado, Denver, CO. United States.
Miguel Paciuc-BejaUniversity of Colorado, Denver, CO. United States.
Roberto Gonzalez-SalinasResearch Department, Asociación para Evitar la Ceguera, IAP, Mexico City, PO 04030, Mexico.
Asociacion Para Evitar la Ceguera en México Hospital Dr. Luis Sánchez Bulnes · MXUniversity of Colorado Denver · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo describe the long-term outcome of a patient with multifocal choroiditis, who underwent surgical removal of a type 2 choroidal neovascular membrane employing 23 G pars plana vitrectomy. OBSERVATIONS: A 50-year-old man was treated with 3 monthly intravitreal bevacizumab injections, but despite treatment, visual acuity continued to worsen from 20/40 to 20/100, and bleeding was not receding. A minimal invasive pars plana vitrectomy was performed for surgical removal of the neovascular complex without any complicating incident. Subsequent visual acuity was 20/25 for more than eleven years. CONCLUSIONS AND IMPORTANCE: Surgical removal of choroidal neovascular membranes employing minimal invasive surgery in addition to anti-VEGF therapy, and OCT evaluation can be a viable approach for selected cases of juxtafoveal type 2 CNV.

Indexed as

Anti-VEGF therapyChoroidal neovascular membranePars plana vitrectomySpectral-domain optical coherence tomography

Identifiers

PMID31193243
PMCPMC6522850
OpenAlexW2944378175

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.